市場調查報告書

高甘油三酯血症治療藥的全球市場:各類型,各類藥物,各流通管道,各地區的市場規模,佔有率,展望,機會分析:2020年-2027年

Hypertriglyceridemia Therapeutics Market, by Type, by Drug Class, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品編碼 952845
出版日期 內容資訊 英文 166 Pages
商品交期: 2-3個工作天內
價格
高甘油三酯血症治療藥的全球市場:各類型,各類藥物,各流通管道,各地區的市場規模,佔有率,展望,機會分析:2020年-2027年 Hypertriglyceridemia Therapeutics Market, by Type, by Drug Class, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2020年07月22日內容資訊: 英文 166 Pages
簡介

高甘油三酸酯血症是由體內甘油三酸酯水準升高引起的疾病。即使膽固醇水準不高,甘油三酯水準升高也會引起心血管疾病和動脈粥樣硬化。高甘油三酸酯血症還會引起心血管疾病,例如胰腺炎和動脈粥樣硬化。

本報告提供全球高甘油三酯血症治療藥市場調查,提供市場力學和法規,新型冠狀病毒感染疾病(COVID-19)大流行病的影響,各類型,各類藥物,各流通管道,各地區的分析,競爭情形和企業簡介等資訊。

目錄

第1章 調查目的與前提條件

第2章 市場概要

  • 報告概要
  • 市場定義和範圍
  • 摘要整理
    • 市場明細 :各類型
    • 市場明細 :各類藥物
    • 市場明細 :各流通管道
    • 市場明細 :各地區
  • 市場機會藍圖

第3章 市場力學,法規,趨勢分析

  • 市場力學
    • 成長促進因素
    • 成長阻礙因素
    • 市場機會
  • 影響分析
  • 技術的進步
  • 主要的動向
  • 收購,合作,聯盟
  • 開發平台分析
  • 專利形勢
  • 價格分析
  • 流行病學

第4章 Covid-19大流行病的影響

  • COVID的前狀況
  • COVID後的需求
  • 開發平台分析
  • 高甘油三酯血症的流行病學研究
  • 建議和指南

第5章 市場分析:各類型,2016年-2027年

  • 簡介
  • 一次性
  • 次發性

第6章 市場分析:各類藥物,2016∼2027年

  • 簡介
  • Statin
  • 纖維狀
  • Omega-3脂肪酸
  • HMG-CoA還原酶抑制劑
  • Niacin

第7章 市場分析:各流通管道,2016∼2027年

  • 簡介
  • 零售藥局
  • 醫院藥局
  • 線上藥局
  • 其他

第8章 市場分析:各地區,2016年-2027年

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 非洲
  • 中東

第9章 競爭情形

  • 企業簡介
    • Sanofi
    • GlaxoSmithKline Plc
    • Biocon
    • Novo Nordisk A/S
    • Tonghua Dongbao Pharmaceutical Co., Ltd.
    • Oramed Pharmaceuticals, Inc.
    • Abbvie
    • Merck & Co., Inc.
    • Wockhardt
    • Pfizer, Inc.
    • Julphar
    • Eli Lilly and Company
    • Bristol-Myers Squibb Company
    • Pfizer Inc.
    • Adocia
    • Hikma Pharmaceutical PLC
    • Lupin Ltd.
    • AbbVie Inc.
    • Wockhardt
    • Zydus Pharmaceuticals Inc.
    • Glenmark
    • Amneal pharmaceutical LLC
    • Aurobindo Pharma
    • Accord Healthcare.

第10章

目錄

Hypertriglyceridemia is a condition and common disorder in which the triglyceride levels in the body increase. This rising levels of triglyceride are majorly associated with predisposing cardiovascular diseases and atherosclerosis, even in the absence of high cholesterol levels. Hypertriglyceridemia also causes pancreatitis, atherosclerosis, and other cardiovascular diseases. Currently, the advancements in treatment of hypertriglyceridemia are helping in recovering the triglyceride levels in the human body.

Market Dynamics

The ongoing research and development of developing novel drugs is expected to propel the global hypertriglyceridemia market growth during the forecast period. For instance, in March 2019, Arrowhead Pharmaceuticals initiated a phase I study of 'ARO-APOC3' for the treatment of hypertriglyceridemia. ARO-APOC3 is the company's second cardio metabolic candidate entering clinical trials, following ARO-ANG3 for the treatment of metabolic diseases and dyslipidemias. Moreover, the growing prevalence of atherosclerosis and other cardiovascular diseases are fueling the market growth. For instance, according to the WHO, about 17.9 million deaths were reported in 2016 due to cardiovascular diseases.

Approvals of drugs and product launches are also expected to create growth opportunities for players operating in the global hypertriglyceridemia market. However, the high costs associated with the treatment and medical care in emerging economies is expected to hinder the market growth in the coming years.

Key features of the study:

  • This report provides in-depth analysis of the global hypertriglyceridemia market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains an attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global hypertriglyceridemia market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
  • Key players covered as a part of this study are Biocon, Sanofi, Novo Nordisk A/S, GlaxoSmithKline Plc, Tonghua Dongbao Pharmaceutical Co., Ltd., Merck & Co., Inc., Oramed Pharmaceuticals, Inc, Wockhardt, Julphar, Pfizer, Inc., Eli Lilly and Company, Adocia, Bristol-Myers Squibb Company, Hikma Pharmaceutical PLC, AbbVie Inc., Lupin Ltd., Accord Healthcare, Zydus Pharmaceuticals Inc., Amneal pharmaceutical LLC, Glenmark, and Aurobindo Pharma.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global hypertriglyceridemia market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers in the hypertriglyceridemia market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global Hypertriglyceridemia Market, By Type:
    • Primary
    • Secondary
  • Global Hypertriglyceridemia Market, By Drug Class:
    • Statins
    • Fibrates
    • Niacin
    • Omega-3 Fatty Acids
    • HMG-CoA Reductase inhibitors
  • Global Hypertriglyceridemia Market, By Distribution Channel:
    • Online Pharmacy
    • Retail Pharmacy
    • Hospital Pharmacy
  • Global Hypertriglyceridemia Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Type:
    • Primary
    • Secondary
      • By Drug Class:
    • Statins
    • Fibrates
    • Niacin
    • Omega-3 Fatty Acids
    • HMG-CoA Reductase inhibitors
      • By Distribution Channel:
    • Online Pharmacy
    • Retail Pharmacy
    • Hospital Pharmacy
    • Others
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Type:
    • Primary
    • Secondary
      • By Drug Class:
    • Statins
    • Fibrates
    • Niacin
    • Omega-3 Fatty Acids
    • HMG-CoA Reductase inhibitors
      • By Distribution Channel:
    • Online Pharmacy
    • Retail Pharmacy
    • Hospital Pharmacy
    • Others
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Type:
    • Primary
    • Secondary
      • By Drug Class:
    • Statins
    • Fibrates
    • Niacin
    • Omega-3 Fatty Acids
    • HMG-CoA Reductase inhibitors
      • By Distribution Channel:
    • Online Pharmacy
    • Retail Pharmacy
    • Hospital Pharmacy
    • Others
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Type:
    • Primary
    • Secondary
      • By Drug Class:
    • Statins
    • Fibrates
    • Niacin
    • Omega-3 Fatty Acids
    • HMG-CoA Reductase inhibitors
      • By Distribution Channel:
    • Online Pharmacy
    • Retail Pharmacy
    • Hospital Pharmacy
    • Others
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Type:
    • Primary
    • Secondary
      • By Drug Class:
    • Statins
    • Fibrates
    • Niacin
    • Omega-3 Fatty Acids
    • HMG-CoA Reductase inhibitors
      • By Distribution Channel:
    • Online Pharmacy
    • Retail Pharmacy
    • Hospital Pharmacy
    • Others
  • Company Profiles
    • Biocon
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Sanofi
    • Novo Nordisk A/S
    • GlaxoSmithKline Plc
    • Tonghua Dongbao Pharmaceutical Co., Ltd.
    • Merck & Co., Inc.
    • Oramed Pharmaceuticals, Inc
    • Wockhardt
    • Julphar
    • Pfizer, Inc.
    • Eli Lilly and Company
    • Adocia
    • Bristol-Myers Squibb Company
    • Hikma Pharmaceutical PLC
    • AbbVie Inc.
    • Lupin Ltd.
    • Accord Healthcare
    • Zydus Pharmaceuticals Inc.
    • Amneal pharmaceutical LLC
    • Glenmark
    • Aurobindo Pharma
  • "*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Type
    • Market Snippet, By Drug Class
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Technological Advancements in Hypertriglyceridemia
  • Key Developments
  • Acquisition, Collaborations & Partnerships
  • Pipeline Analysis
  • Patent Landscape
  • Pricing Analysis
  • Epidemiology

4. Global Hypertriglyceridemia Therapeutics Market, Impact of Coronavirus (Covid-19) Pandemic

  • Pre-COVID situation
  • Post-COVID demand
  • Pipeline Analysis
  • Hypertriglyceridemia Epidemiology Study
  • Recommendations and Guidelines By Regulatory Bodies

5. Global Hypertriglyceridemia Therapeutics Market, By Type, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Primary
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Secondary
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

6. Global Hypertriglyceridemia Therapeutics Market, By Drug Class, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Statins
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Fibrates
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Omega-3 Fatty Acids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • HMG-CoA Reductase inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Niacin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

7. Global Hypertriglyceridemia Therapeutics Market, By Distribution Channel, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Retail Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Hospitals Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Online Pharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

8. Global Hypertriglyceridemia Therapeutics Market, By Region, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027(%)
    • Y-o-Y Growth Analysis, By Region, 2017 -2027
    • Regional Trends
  • North America
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East

9. Competitive Landscape

  • Company Profiles
    • Sanofi
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • GlaxoSmithKline Plc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Biocon
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Novo Nordisk A/S
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Tonghua Dongbao Pharmaceutical Co., Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Oramed Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Abbvie
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Merck & Co., Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Wockhardt
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Julphar
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bristol-Myers Squibb Company
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Adocia
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Hikma Pharmaceutical PLC
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Lupin Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • AbbVie Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Wockhardt
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Zydus Pharmaceuticals Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Glenmark
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Amneal pharmaceutical LLC
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Aurobindo Pharma
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Accord Healthcare.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

10. Section

  • References
  • Research Methodology
  • About Us and Sales Contact